CD38 and neoplasm: A fully human CD38xCD47 bispecific antibody, ISB 1442, consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity induced blocking of proximal CD47 receptors on the same cell while preventing on-target off-tumor binding on healthy cells.